IRLAB publishes preclinical data on mesdopetam in the esteemed European Journal of Neuroscience
Gothenburg, March 12, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that preclinical data on mesdopetam has been published in the prestigious, peer-reviewed medical journal European Journal of Neuroscience, EJN. The data provide new insights into the system-level mechanisms behind the antidyskinetic effect of mesdopetam and suggest potential additional benefits in the treatment of Parkinson’s related psychosis.
Read More >Watch IRLAB’s
Capital Markets Day 2023!
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >